Analysts Set Apyx Medical Corporation (NASDAQ:APYX) Price Target at $6.50

Apyx Medical Corporation (NASDAQ:APYX) has earned an average rating of “Moderate Buy” from the six brokerages that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, three have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $6.50.

APYX has been the topic of a number of research analyst reports. Wall Street Zen downgraded Apyx Medical from a “buy” rating to a “hold” rating in a report on Sunday, April 26th. Craig Hallum increased their target price on Apyx Medical from $5.00 to $6.00 and gave the company a “buy” rating in a report on Wednesday, March 11th. BTIG Research raised Apyx Medical from a “neutral” rating to a “buy” rating and set a $6.00 target price on the stock in a report on Wednesday, March 11th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Apyx Medical in a report on Friday, March 27th.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. AIGH Capital Management LLC bought a new position in Apyx Medical in the fourth quarter valued at about $3,867,000. Huntleigh Advisors Inc. bought a new position in Apyx Medical in the fourth quarter valued at about $827,000. Renaissance Technologies LLC lifted its holdings in Apyx Medical by 37.2% in the first quarter. Renaissance Technologies LLC now owns 302,395 shares of the company’s stock valued at $1,116,000 after acquiring an additional 82,000 shares during the period. Sei Investments Co. lifted its holdings in Apyx Medical by 298.6% in the first quarter. Sei Investments Co. now owns 598,255 shares of the company’s stock valued at $2,208,000 after acquiring an additional 448,174 shares during the period. Finally, Nwam LLC bought a new position in Apyx Medical in the first quarter valued at about $47,000. Institutional investors own 55.33% of the company’s stock.

Apyx Medical Trading Up 1.2%

Shares of NASDAQ:APYX opened at $4.17 on Friday. The company has a market cap of $174.60 million, a P/E ratio of -18.95 and a beta of 1.39. The company has a debt-to-equity ratio of 2.68, a current ratio of 5.80 and a quick ratio of 4.79. Apyx Medical has a 1 year low of $1.59 and a 1 year high of $5.08. The stock’s fifty day moving average price is $4.00 and its 200-day moving average price is $3.83.

Apyx Medical (NASDAQ:APYX) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.06. The firm had revenue of $12.49 million for the quarter, compared to the consensus estimate of $10.53 million. Apyx Medical had a negative return on equity of 88.47% and a negative net margin of 16.40%.

Apyx Medical Company Profile

Apyx Medical (NASDAQ: APYX) is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company’s product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology.

Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions.